An initial analysis at 2.75 years showed a nonsignificant trend in disease-free survival benefit, indicating an improved outcome with exemestane versus tamoxifen in the intent to treat population. 32 Excluding patients who have never received a study drug, disease-free survival significantly improved with exemestane.
← all excerpts
Tamoxifen in early-stage estrogen receptor-positive breast cancer: overview of clinical use and molecular biomarkers for patient selection.
1
—
—